Supita Tanasawet (Thailand)
Faculty of Science, Prince of Songkla University Department of Anatomy, Faculty of ScienceAuthor Of 1 Presentation
DESIGN OF POLY(DOPA)-BASED NANOPARTICLE FOR PARKINSON’S DISEASE TREATMENT WITH SUPPRESSING DYSKINESIA
- Yukio Nagasaki (Japan)
Abstract
Background and Aims:
The major cause of Parkinson's disease (PD) is thought to be the loss of dopaminergic substantia nigra neurons and the formation of alpha-synuclein-containing Lewy bodies. Although dopamine supplementation is a vital therapy, it is not facile to cross the BBB. 3,4-Dihydroxyphenylalanine (L-DOPA), a dopamine precursor, is one of the main drugs to treat PD since L-DOPA can cross the BBB better than dopamine; however, there are strong demands to develop further effective drugs due to the short half-life and several adverse effects such as dyskinesia. In this study, we studied new drugs based on novel molecular self-assembling at overcoming the drawbacks of L-DOPA and creating safe and effective Parkinson's disease drugs, viz., a nanoparticle consists of poly(diacetyl L-DOPA) was designed, which improved the controlled release of L-DOPA and improved the therapeutic effects, suppressing its adverse effects.
Methods:
A newly designed hydrophilic-hydrophobic block copolymer poly(ethylene glycol)-b-poly (L-DOPA(diacetyl)) forms self-assembling nano-sized particle (NanoDOPA), which is examined to the effect on Parkinson's disease model mice.
Results:
NanoDOPA significantly prolonged the retention of L-DOPA in the blood (mouse; n=3) and not only showed recovery in Parkinson's disease mice (n=8) but also reduced Dyskinesia symptoms (n=8).
Conclusions:
NanoDOPA is anticipated as a new high-performance Parkinson's disease drug.